Scientists in the UK have raised concerns about the “deadly virus” due to climate change. The UK government’s Science, Innovation, and Technology Committee received information about the major threat posed by the Crimean-Congo hemorrhagic fever (CCHF), a deadly virus with a high fatality rate. Scientists alerted the committee about the CCHF’s potential impact on the country. This article is on the impact and the preventive measure that could be taken against CCHF.
What is the Crimean-Congo Haemorrhagic Fever (CCHF)?
This is caused by a tick-borne virus from the Bunyaviridae family, specifically the Nairovirus. This virus is common in Africa, the Balkans, the Middle East, and certain Asian countries.
With a high infected rate from 10% to 40%. CCHF is considered a high-risk disease by the World Health Organization (WHO).
Concerns of Detection and Spread in the UK
Scientists stressed the fact that infections may go unnoticed by NHS doctors. As these diseases were not previously expected in the UK. Prof James Wood from Cambridge University confirms that it is highly likely that the virus will reach the UK. But the precise timing and exact viruses remain uncertain.
Climate Change and the Risk of Emerging Diseases
The higher temperature in the UK is expected to create favorable conditions for the spread of other diseases. This includes Rift Valley fever, breakbone fever, and Zika. Prof Sir Peter Horby from Oxford University stresses that climate transformation is changing the traditional geographical boundaries of various illnesses. Leading to the spread of diseases like dengue beyond their typical regions.
Transmission, Symptoms, and Lack of Treatment
Due to the high percentage of ticks carrying the CCHF virus. The climate change-induced movement of livestock and wildlife rises the likelihood of transmission from animals to humans. Dr. Sabine Kapasi, a Public Health Leader, informs us of the disease’s high rate of fatality and lack of effective treatments or vaccines. She explains the symptoms of CCHF, including headache, muscle aches, fever, and gastrointestinal issues.
Managing CCHF and Future Concerns
Dr. Kapasi warns that there is no specific treatment for CCHF. Supportive care and symptom management are initial approaches, although the antiviral drug ribavirin has shown some apparent benefits.
In conclusion, scientists in the UK are alarmed about the arrival of the deadly Crimean-Congo hemorrhagic fever due to weather changes. With its high fatality rate and lack of effective treatments. This emerging threat stresses the urgent need for more awareness, surveillance, and preventive measures to reduce the impact of climate change on public health.
